GLOBEIMMUNE INCORPORATED (OTCMKTS:GBIM) had a decrease of 6.48% in short interest. GBIM’s SI was 10,100 shares in December as released by FINRA. Its down 6.48% from 10,800 shares previously. With 16,000 avg volume, 1 days are for GLOBEIMMUNE INCORPORATED (OTCMKTS:GBIM)’s short sellers to cover GBIM’s short positions. The stock increased 44.19% or $0.199 during the last trading session, reaching $0.649. About 305 shares traded. GlobeImmune, Inc. (OTCMKTS:GBIM) has 0.00% since December 2, 2016 and is . It has underperformed by 16.70% the S&P500.
Commerzbank Aktiengesellschaft increased Kinross Gold Corp (KGC) stake by 56.06% reported in 2017Q2 SEC filing. Commerzbank Aktiengesellschaft acquired 730,634 shares as Kinross Gold Corp (KGC)’s stock rose 9.54%. The Commerzbank Aktiengesellschaft holds 2.03M shares with $8.28 million value, up from 1.30 million last quarter. Kinross Gold Corp now has $5.14 billion valuation. The stock decreased 1.68% or $0.07 during the last trading session, reaching $4.09. About 11.15M shares traded or 25.88% up from the average. Kinross Gold Corporation (NYSE:KGC) has declined 13.79% since December 2, 2016 and is downtrending. It has underperformed by 30.49% the S&P500.
Among 17 analysts covering Kinross Gold Corporation (NYSE:KGC), 8 have Buy rating, 0 Sell and 9 Hold. Therefore 47% are positive. Kinross Gold Corporation had 59 analyst reports since July 24, 2015 according to SRatingsIntel. Citigroup upgraded the stock to “Neutral” rating in Friday, September 1 report. Bank of America upgraded the stock to “Buy” rating in Tuesday, May 23 report. BMO Capital Markets maintained it with “Buy” rating and $5.25 target in Monday, September 18 report. The stock of Kinross Gold Corporation (NYSE:KGC) earned “Outperform” rating by Raymond James on Thursday, June 15. TD Securities upgraded Kinross Gold Corporation (NYSE:KGC) on Thursday, March 31 to “Buy” rating. The rating was upgraded by Credit Suisse to “Outperform” on Tuesday, February 9. IBC initiated the shares of KGC in report on Friday, July 24 with “Sector Perform” rating. UBS downgraded the shares of KGC in report on Thursday, February 25 to “Neutral” rating. BMO Capital Markets maintained it with “Buy” rating and $5.2500 target in Wednesday, August 2 report. The firm earned “Neutral” rating on Tuesday, November 22 by Bank of America.
Commerzbank Aktiengesellschaft decreased Abbvie Inc (NYSE:ABBV) stake by 51,885 shares to 18,361 valued at $1.33M in 2017Q2. It also reduced First Majestic Silver Corp (NYSE:AG) stake by 274,559 shares and now owns 343,778 shares. Halliburton Co (NYSE:HAL) was reduced too.
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. The company has market cap of $3.73 million. The Company’s product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. It currently has negative earnings. The firm is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.